OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa.
Pseudomonas aeruginosa 455, isolated in Ankara, Turkey, produced a pI 6.2 beta-lactamase determined by plasmid pMLH53 and resisted all beta-lactams except carbapenems. This beta-lactamase, named OXA-14, corresponded to OXA-10 (PSE-2) except that aspartate replaced glycine at position 157 and thus is intermediate between OXA-10 and OXA-11, which has aspartate at position 157 and a further substitution at position 143.
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001483:Base Sequence; D003227:Conjugation, Genetic; D004269:DNA, Bacterial / Q000032:analysis; D006801:Humans; D006868:Hydrolysis; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D008970:Molecular Weight; D010957:Plasmids; D011552:Pseudomonas Infections / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000201:enzymology*; D018440:beta-Lactam Resistance / Q000235:genetics; D001618:beta-Lactamases / Q000032:analysis / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial; C096781:beta-lactamase OXA-14; D001618:beta-Lactamases